US FDA Classifies Aurobindo Pharma's Eugia Unit-III Facility as Official Action Indicated
The U.S. Food and Drug Administration (FDA) has classified Aurobindo Pharma's Eugia Pharma Specialities Unit-III formulation manufacturing facility in Hyderabad as "Official Action Indicated" (OAI) following an inspection from January 27 to February 6, 2026. The FDA issued 11 observations, recommending regulatory or administrative actions. This is the second Eugia plant to receive an OAI classification. Aurobindo Pharma stated it expects no impact on its financials or operations and remains committed to quality standards.